Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.05.15
Views: 2382
Rating:

Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA

Dr Schuchter gives an expert commentary at ASCO 2015 on immunotherapy data presented on the first day:

- A 132-patient study indicating that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC)

- Genomic marker predicts anti-PD-1 response in several cancers

- Findings from a phase I/II study that suggest that nivolumab is safe and effective in advanced liver cancer

- Randomised phase III study indicates PD-1 immunotherapy is an effective treatment option for NSCLC

Read the news article or watch the press conference for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation